

Molecular Farming: Strategies, Expression Systems and Bio-Safety Considerations

KAFEEL AHMAD

Department of Biology, University of Leicester, Leicester, United Kingdom

Abstract

AHMAD K. (2014): **Molecular farming: strategies, expression systems and bio-safety considerations**. Czech J. Genet. Plant Breed., 50: 1–10.

Molecular farming is an experimental application of biotechnology that involves the genetic modification of crops for the production of proteins and chemicals for medicinal and commercial purposes. The vast majority in the developing world cannot afford the high cost of therapeutics produced by existing methods. We need to produce not only new therapeutics but also cheaper versions of the existing ones. Molecular farming could offer a viable option for this growing need for biopharmaceuticals. Plant made therapeutics are cheaper, safer, can be abundantly produced and easily stored. Here, strategies and approaches utilized in plant molecular farming are discussed. Furthermore, the bio-safety considerations related to this emerging field are also discussed.

Keywords: biopharmaceuticals; recombinant proteins; rhizosecretion; therapeutics; transformation

Molecular farming can be described as an experimental application of biotechnology to genetically engineered crops in order to produce proteins and chemicals for pharmaceutical and other commercial interests (FRANKEN *et al.* 1997). Evidence of using plants for medicinal purposes can be traced back to as early as the Neanderthal period (about 130 000 years ago), when plants were used to aid healing of wounds (KLEINER 1995). Romans used willow bark for the treatment of fever which was later identified to contain aspirin (MEWETT *et al.* 2007). During the 16th century medicinal plants were grown for teaching medicine and as a source of treatment for various diseases (AKERELE 1993). The use of plants and plant extracts for medicinal purposes flourished until the 17th century when more scientific pharmacological treatments were recommended (TREVELYAN 1993; WINSLOW & KROLL 1998). One fourth of the currently used medicines still have a plant origin (WINSLOW & KROLL 1998).

Genetic engineering has recently opened up new opportunities for using plants as production factories for biopharmaceuticals. Human growth hormone was the first pharmaceutically important protein that was expressed in transgenic tobacco (BARTA *et al.* 1986). Since then transgenic plants expressing vaccines, therapeutics, industrial enzymes, anti-

bodies, nutraceuticals, and other pharmaceutical proteins have been produced (KREBBERS *et al.* 1992; WHITELAM *et al.* 1993; MA *et al.* 1994; HERBERS & SONNEWALD 1999; MA *et al.* 2005).

Historically both prokaryotic (GEORGIU & BOWDEN 1991) and eukaryotic (HARASHIMA 1994; LUBON *et al.* 1996) systems have been utilized to express recombinant proteins. Prokaryotic production systems are comparatively inexpensive and convenient compared to mammalian systems in terms of the technology/equipment required.

However, many mammalian proteins require post-translational modifications such as protein glycosylation for their biological activity which cannot be performed by prokaryotic production systems. The use of prokaryotic expression systems is therefore perhaps limited. On the other hand, the cost of producing proteins in mammalian cells is very high in terms of maintaining cell cultures and scale up. In contrast, pathways of protein synthesis and modification in plants are very similar to those in animals facilitating protein modification analogous to that seen in animal cells (CABANES-MACHETEAU *et al.* 1999). Mass production of heterologous proteins and biopharmaceuticals in plants can be achieved at much lower costs and contamination or co-purification of human or animal pathogens

is also avoided (EVANGELISTA *et al.* 1988; VERWOERD *et al.* 1995; GIDDINGS *et al.* 2000; WHITELAM 2000; ZIEGLER *et al.* 2000). Additionally, plants possess natural protein storage organs and their seeds are easily distributed, allowing local production (WHITELAM *et al.* 1993; WHITELAM 2000).

Although protein glycosylation pathways are predominantly similar between humans and plants, minor differences do exist in glycosylation. These include, for example, the absence of terminal sialic acid residues in the plant derived glycan chains and the existence of plant based residues (CABANES-MACHETEAU *et al.* 1999). These differences could make a recombinant protein inactive, harmful or immunogenic. Hence, these glycosylation pathways need to be humanized for expression of therapeutic proteins. For example, human glycosyltransferase could be co-engineered into plants along with the transgene of interest (BAKKER *et al.* 2001). The recombinant protein could also be targeted to the endoplasmic reticulum, which could result not only in the lack of plant specific glycosylation but also in increased accumulation of recombinant protein (CABANES-MACHETEAU *et al.* 1999; LOOS & STEINKELLNER 2012; NAGELS *et al.* 2012).

Strategies for optimum protein production

Selection of plant type for transformation. Theoretically, any type of plant can be transformed; however, it is useful to use plants which are well studied and characterized allowing effective risk assessment and tracking of the transgene of interest. The appropriate type of plant selection is important for efficient protein production. Proper consideration should be given to use plants species with the least chance(s) of dissemination of transgene/gene product to other plants/environment. Use of self-pollinating plants can reduce chances of gene transfer to other plants. The choice of host plant also depends on the recombinant protein to be expressed, the host plant life cycle, biomass yield and production costs (SHARMA & SHARMA 2009). If the protein is to be expressed in green tissues, then leafy plants like tobacco may serve as an ideal plant with the huge biomass production capacity (FISCHER & EMANS 2000). Tobacco has been used as the system of choice for a number of plant-derived recombinant proteins (SEXTON *et al.* 2009). Tobacco has the advantage of producing huge quantities of green leaf material per acre. The agrobacterium-mediated transformation is highly efficient in tobacco. The plant has a prolific seed production which could facilitate

biomass scale-up. Tobacco plants mainly self-pollinate, so there is little risk of transfer of genetic material to other plants. Tobacco is also a non-food crop, so there is little risk of food chain contamination (MA *et al.* 2003). An important issue in the use of tobacco as production system is the presence of undesirable high amounts of nicotine in tobacco leaves that could make the expressed proteins less usable. However, there are cultivars available in tobacco that produce reduced levels of unwanted secondary metabolites like nicotine (MENASSA *et al.* 2001). Alternatively, efficient purification systems for the removal of unwanted nicotine could be utilized to get nicotine-free recombinant proteins (FU *et al.* 2010). Other leafy crops that have been used for recombinant protein production include spinach (YUSIBOV *et al.* 2002), lettuce (RUHLMAN *et al.* 2007) and lucerne (KHOUDI *et al.* 1999). A disadvantage associated with leafy crops is that the expressed proteins may be unstable in the leaf environment which could interfere with yield and quality of the protein in question. Also the phenolic compounds released during an extraction process could be detrimental to downstream processing (MA *et al.* 2003). Cereals and legumes can also be used as alternative production systems to overcome some of these problems (RADEMACHER *et al.* 2008; TSUBOI *et al.* 2008). Seeds have specialised storage compartments which help in reducing protein degradation, the exposure of the recombinant protein to phenolic compounds is also avoided thus improving downstream processing (MA *et al.* 2003). A number of cereal crops like maize (RADEMACHER *et al.* 2008), rice (QIAN *et al.* 2008) and wheat (TSUBOI *et al.* 2008) have been utilized for recombinant protein production. Legumes like pea (PERRIN *et al.* 2000) and soybean (MORAVEC *et al.* 2007) have also been used to express foreign proteins. Oil crops offer another inexpensive platform for the expression of recombinant proteins. With oleosin fusion technology, developed by SemBioSys Genetics Inc. (<http://www.sembiosys.com/>), the recombinant protein gene sequence is fused to the sequence of an oil body specific endogenous protein oleosin in rapeseed and safflower, after purification the protein is separated by an endoprotease digestion (SCHILLBERG *et al.* 2005). Potato has also been exploited in the production of vaccines (MA *et al.* 2003). Other plants that have been used for biopharming include tomato (SANDHU *et al.* 2000), carrot (DANIELL *et al.* 2005), banana (TRIVEDI & NATH 2004) and papayas (CARTER & LANGRIDGE 2002).

Sub-cellular targeting. Consideration should be given to where the protein of interest should be

produced in plants. Targeting to sub-cellular compartments can help increase the production and recovery of the target proteins (FISCHER & EMANS 2000). The endoplasmic reticulum is an important site for the processing, disulphide bond formation, assembly and glycosylation of proteins (HELENIUS & AEBI 2001). Targeting proteins to the apoplast can result in a high level of expression and better downstream processing; however, the endoplasmic reticulum retention has resulted in 10- to 100-fold higher yields (CONRAD & FIEDLER 1998). Another important sub-cellular compartment with capability of several hundredfold accumulation of recombinant proteins is the chloroplast which is capable of correct folding and disulphide bond formation, but is not capable of glycosylation (RUF *et al.* 2001). Recombinant proteins have also been targeted to protein storage vacuoles (STOGER *et al.* 2000). Rhizosecretion or the secretion of recombinant protein in the hydroponic medium in roots is another strategy that can help in simplifying the downstream processing and increasing the protein yield (DRAKE *et al.* 2009).

Plant transformation types

Nuclear transformation. Stable transformation involves the integration of foreign gene/s in the genome of the plant. This can be achieved either by agrobacterium-mediated transformation of dicotyledonous plants or through biolistic delivery (gene-gun) methods in monocots. These transformations result in heritable expression of recombinant protein, which is stable from generation to generation, so it is good for long-term production of recombinant proteins. However, it is time consuming as to develop stably transformed plants takes months or years depending on the plant type used for recombinant protein expression. The strategy is also costly compared to transient expression. With nuclear transformation it is possible to target the protein of interest to various sub-cellular locations such as the nucleus, cytoplasm, endoplasmic reticulum, plastids, vacuole and apoplast. Correct sub-cellular targeting makes it possible for the correct posttranslational modifications to be carried out on the expressed protein. Another advantage of nuclear transformation is the high level of scalability that is possible as the stably transformed plants could be theoretically grown on huge acreages anywhere in the world. However, there is an inherent chance of transfer of genetic material to other crops, so special regulatory measures must be taken to prevent transgene escape to non-target crops.

Transient expression. During transient expression the foreign genetic material does not integrate into the genome of the plant. This can be achieved through agro-infiltration (using agro-bacteria), viral vectors or through biolistics. Transient expression offers some advantages, as data on whether a particular gene is being expressed or not can be obtained in days (KAPILA *et al.* 1996). Transient expression can be used in pilot experiments before proceeding to the time consuming and costly stable transformation. Problems in protein expression can be identified and corrected so that the chances of producing the desired protein through stable transformation are made more likely. Through agro-infiltration a number of genes can be expressed at the same time which can help in studying the combined effect of multiple transgenes which are expressed (JOHANSEN & CARRINGTON 2001). However, the yield of expressed protein is normally lower and the plant material requires processing immediately as due to the perishable nature of leaves degradation during the storage of plant tissue will result in further loss of the protein. Recently SAINSBURY *et al.* (2009) have developed a number of binary vectors called pEAQ vectors for transient expression which could give high levels of transgene expression in a very short time. Furthermore, these vectors also allow the simultaneous expression of more than one protein.

Chloroplast transformation. The gene of interest can also be incorporated into the chloroplast genome. The commonly used method to transform chloroplasts involves using a gene gun to incorporate the transgene into the chloroplast genome (DANIELL 2006). A mature leaf cell contains up to 100 chloroplasts and each chloroplast can contain up to 100 copies of chloroplast genome. It is, therefore, likely that a higher yield of foreign protein could be produced from chloroplast transformation than from nuclear transformation (DANIELL 2006). The amount of recombinant protein could be as high as 46% of total soluble protein (DE COSA *et al.* 2001). Since the chloroplast is prokaryotic in nature, gene silencing is not observed unlike nuclear transformation. As the expressed protein is confined to the chloroplast, therefore it has no toxic effects on the host plant (DANIELL 2006). Chloroplasts are maternally inherited; therefore, transfer to other plants through pollen is avoided. The technique is most commonly used in tobacco. However, the chloroplast does not provide any post-translational modifications such as glycosylation and hence the technology is not adopted widely (BOEHM 2007). As with nuclear

transformation, chloroplast transformation is also time consuming as it requires the generation of stably transformed plants. Furthermore, different cloning vectors are required for transformation of different plant species (VERMA & DANIELL 2007).

Stability of recombinant DNA inside plant

One possible outcome of insertion of recombinant DNA into the plant genome is that the recombinant DNA can sometimes undergo inactivation, preventing its expression inside the plant cell. Recombinant DNA inactivation has been attributed to multiple copy integration, different base composition between recombinant DNA and the integration site, overexpression effects and detrimental effects of sequences adjacent to the recombinant DNA integration site (FINNEGAN & McELROY 1994). The presence of repeated homologous sequences, recombinant DNA methylation and co-suppression can also lead to recombinant DNA inactivation (MEYER & SAEDLER 1996). Recombinant DNA inactivation can be avoided by selecting lines with a single insertion of the transgene, not using repetitive homologous sequences, selecting stable recombinant lines and creating site-specific recombination systems (FINNEGAN & McELROY 1994).

Optimizing foreign gene sequences for expressing in plants

Plants have a different codon usage bias than animals, however foreign DNA can be optimized for expression in plants to increase translation and therefore obtain higher protein yields (KUSNADI *et al.* 1998). Expression can be increased further by the use of tissue specific promoters, improving transcript stability and the use of viral sequences for translational enhancement (GALLIE 1998). The 35S promoter is suitable for dicotyledonous plants while the maize ubiquitin-1 promoter is normally used for monocot plants (MA *et al.* 1995; CHRISTENSEN & QUAIL 1996). The use of tissue specific promoters can also help in avoiding adverse effects on plant growth, development and environment (CRAMER *et al.* 1999; STÖGER *et al.* 2000).

Protein expression can be increased by the use of introns in the recombinant DNA molecule (MAAS *et al.* 1991). However, the exact mechanism how introns enhance protein expression is not known. It has been found that transgene translation can be enhanced by the addition of untranslated leader sequence of alfalfa mosaic virus mRNA 4 (DATLA *et al.* 1993). The

stability of mRNA is also influenced by the polyadenylation sites in plant cells (INGELBRECHT *et al.* 1989; HUNT 1994). These sites protect enzymatic degradation of mRNA. There also exist specific recognition sites that result in RNA degradation (SULLIVAN & GREEN 1993). Some of these recognition sites have been discovered and are supposed to be involved in mRNA degradation as a result of their interaction with specific binding factors (TAYLOR & GREEN 1995). It may be useful to screen for these sites and remove them by modifying the gene of interest to increase gene expression. Specific protein initiation sequences such as the Kozak sequence have been found to help in efficient translation in animals; however, this may be different in plants (LUTCKE *et al.* 1987; CAVENER & RAY 1991). The level of amino acid can also be a limiting factor in the expression of particular proteins, it may, therefore, be necessary to alter amino acid synthesis pathways for the expression of some particular proteins (MATTHEWS & HUGHES 1993, SINGH & MATTHEWS 1994).

Expression of multiple genes

Traditionally, plants have been transformed with single genes to improve plant characteristics, to study plant gene expression and to express foreign proteins for industrial or pharmaceutical purposes. However, there are situations when the transformation of plants with multiple genes is desirable. These include improving plants for multigenic traits, improving or altering metabolic pathways, expressing multimeric foreign proteins and expressing multiple enzymes involved in the synthesis of various compounds. Multiple gene engineering can be achieved in different ways.

(1) IRESs or internal ribosome entry sites have been used primarily for the expression of two genes in the form of a bicistronic message (HELLEN & SARNOV 2001; ALLERA-MOREAU *et al.* 2006; SASAKI *et al.* 2008). IRESs are nucleotide sequences that recruit eukaryotic ribosomes to mRNA to initiate protein translation in the middle of the mRNA molecule without the requirement for a 5' cap that is normally needed for translation initiation (PELLETIER & SONENBERG 1988). The main drawback of using IRES for multiple protein expression is that the expression of the IRES regulated gene is lower than the cap-dependent gene upstream of IRES sequence (KAUFMAN *et al.* 1991; ZHOU *et al.* 1998; HOUDEBINE & ATTAL 1999).

(2) Independent transgenic lines expressing one gene can be developed and then all the transgenic lines can be crossed together to combine all the genes respon-

sible for the trait under study in a single plant (MA *et al.* 1995). However, this strategy is time consuming and laborious and cannot be used for many genes as the occurrence of transgenes on different loci makes the process of obtaining and maintaining homozygous plants complicated. Furthermore, the strategy cannot be used for vegetatively propagated plants.

(3) A plant can be sequentially transformed with the transgenes of interest one by one or in units consisting of more than one gene. However, this is time consuming again and a different selection marker is required for each transformation event, and the number of available markers is limited.

(4) The multiple genes can be expressed in the form of multiple expression cassettes linked together, each expression cassette with its own promoter and terminator (SLATER *et al.* 1999; GODERIS *et al.* 2002). However, multiple copies of the same promoter used for the transgenes of interest can lead to gene silencing (VAN DEN ELZEN *et al.* 1993; MATZKE & MATZKE 1998) and there is only a limited choice of different promoters available to overcome this problem.

(5) Co-transformation is another method for multiple gene expression that involves the simultaneous transformation of plant with the transgenes of interest through biolistics or through agrobacterium-mediated transformation (ZHANG & FAUQUET 1998; LI *et al.* 2003). Again, the problem with co-transformation is that in many cases the plant cannot be efficiently transformed with all the genes of interest and variable integrations of the genes involved can occur, which makes the subsequent characterization difficult.

(6) Multiple genes can also be expressed in the chloroplast genome (DANIELL & DHINGRA 2002); however, this method is not suitable for proteins that need to be targeted to cell compartments other than chloroplast.

Purification and downstream processing of recombinant proteins

Downstream processing refers to the recovery and purification of the recombinant protein from plants. Recovery usually involves processing/fractionating of the plant tissue, protein extraction, solid-liquid separation, and concentration, whereas purification consists of immunoprecipitation, liquid-liquid extraction, membrane filtration, chromatography, etc. Processing of leaves requires special attention. Leaves must be processed immediately after harvest or must be frozen to prevent degradation of proteins by proteases, while seeds can be stored for longer

periods as there are fewer chances of degradation of recombinant proteins expressed in the seed. The use of cell secretion systems could also be beneficial as there is no need to disrupt plant cells during recovery, so the release of phenolic compounds could be avoided, however, in the culture medium the recombinant protein may not be stable (FISCHER *et al.* 2004). Another way of facilitating protein recovery is the use of affinity tags. Protein tags should be removed after purification to restore the structure of the purified protein to its native state (FISCHER *et al.* 2004). Oleosin fusion technology, developed by SemBioSys Genetics Inc. (<http://www.sembiosys.com/>), is another system in which the recombinant protein gene sequence is fused to the sequence of an oil body specific endogenous protein oleosin in rapeseed and safflower, after purification the protein is separated by an endoprotease digestion (SCHILLBERG *et al.* 2005). Problems encountered during protein extraction primarily include proteolytic degradation and structural modification due to the reaction with phenolic compounds. When devising a strategy for heterologous protein production in plants, proper consideration should be given to downstream processing feasibility of the recombinant protein to get optimum protein yield.

Economics of plant made pharmaceuticals

The economic prospects for plant made proteins are quite high in comparison with conventional systems. There is a huge demand for many pharmaceutical proteins. Thanks to the scalability of transgenic plants this demand can be fulfilled at fractional costs of the traditional systems. It is possible to obtain yields of kilogram quantities of recombinant protein from just one hectare of transgenic tobacco (FISCHER & EMANS 2000). Even if the expression level of protein in maize is 1% of dry weight and its recovery is only 50%, the cost of its production may still be only 2–10% of microbial systems and may be even lower than that for mammalian systems (TWYMAN *et al.* 2003; CHEN *et al.* 2005). It has been estimated that at 20% total soluble seed protein expression level, one bushel (25 kg) of maize can produce the same amount of avidin as one tonne of chicken eggs and the cost is only 0.5% of that of chicken eggs (HOOD 2004). Several companies at the moment are involved in the commercial production of plant made recombinant proteins. For example, Maltagen Forshung GmbH has been able to produce 3 g human albumin, 2 g lactoferrin and 1.5 g lysozyme per kg of barley

seeds, respectively (<http://www.maltagen.de/PDF/Products.pdf>). Several plant molecular farming products are currently at the advanced stages of development and some have been produced commercially. Plants also have the advantage that several types of proteins like the recombinant subunit vaccines can be administered in the form of raw or partially processed fruits and vegetables (MASON *et al.* 2002). However, it has been quite hard for the industry to grow because of very strict regulations. The consumers' concerns about the safety of plant made pharmaceuticals further add to the difficulties involved in commercializing molecular farming products. Once the regulatory hurdles, issues over public confidence can be overcome, and purification and downstream processing is simplified, then plant produced molecular farming products have the potential to bring about the cost effective and large-scale production of some important products, many with high medical value.

Bio-safety and monitoring

Public concern about the introduction of genetically modified crops represents one of the most challenging issues. Lack of communication among the authorities dealing with research, bio-safety and trade is an important issue that has hindered developments in molecular farming (RAMESSAR *et al.* 2008). The long-term impact of molecular farming products on the environment is difficult to assess. An important concern is the contamination of the food chain with plant made pharmaceuticals. This could happen as a result of transfer of genetic material from transgenic plants to food crops, using the same equipment for harvesting and processing of transgenic and food crops without proper decontamination, and growing food crops in the same field where a transgenic crop was grown previously and no decontamination was carried out (RIGANO & WALMSLEY 2005). To avoid the food chain contamination, strict regulation needs to be put in place such as geographically isolating the transgenic crop, growing in greenhouses instead of open fields, and harvesting and processing transgenic plants using separate equipment or properly decontaminating the equipment if the same equipment is also applied to food crops (RIGANO & WALMSLEY 2005). Containment can also be achieved by using male-sterile traits and using chloroplast transformation of plants. As the chloroplast genome is maternally inherited, the chances of transgene spread through pollen are controlled. It is also important

to label genetically modified products so that the consumer has the choice to select according to his/her own preferences. Regulatory agencies are facing a number of challenges regarding the regulation of transgenic crops. Each molecular farming product and each host system is unique so each case needs to be handled separately. The 0.5% presence of transgenic material in non-transgenic food or feed has been allowed by the European Parliament and the Council of the European Union in cases where the presence of transgenic material is unavoidable and its negative effects are dominated by its benefits (European Parliament 2003). Efforts to confine transgenics and reduce environmental exposure have been made recently (MA *et al.* 2003; CHEN *et al.* 2005; SPARROW & TWYMAN 2009), however, these regulations are still in infancy and much more effort is needed to overcome problems regarding regulations of molecular farming products.

CONCLUSION

Till date a number of pharmaceutical proteins have been expressed in plants. Plants offer a cheaper and safer source of biopharmaceuticals. However, there are a number of technical limitations molecular farming is facing. These mostly include the low yields and recovery of the expressed proteins. Currently, much effort is being devoted to overcome these limitations. Furthermore, there are bio-safety and environmental issues concerning molecular farming. Efforts are being devoted to overcome this, however, a lot more has to be done to make molecular farming products a success.

References

- AKERELE O. (1993): Nature's medicinal bounty: don't throw it away. *World Health Forum*, **14**: 390–395.
- ALLERA-MOREAU C., CHOMARAT P., AUDINOT V., COGÉ F., GILLARD M., MARTINEAU Y., BOUTIN J.A., PRATS A.C. (2006): The use of IRES-based bicistronic vectors allows the stable expression of recombinant G-protein coupled receptors such as NPY5 and histamine 4. *Biochimie*, **88**: 737–746.
- BAKKER H., BARDOR M., MOLTHOFF J.W., GOMORD V., ELBERS I., STEVENS L.H., BOSCH D. (2001): Galactose-extended glycans of antibodies produced by transgenic plants. *Proceedings of the National Academy of Sciences of the United States of America*, **98**: 2899–2904.
- BARTA A., SOMMERGRUBER K., THOMPSON D., HARTMUTH K., MATZKE M.A., MATZKE A.J.M. (1986): The expression

- of nopaline synthase human growth hormone chimaeric gene in transformed tobacco and sunflower callus tissue. *Plant Molecular Biology*, **6**: 347–357.
- BOEHM R. (2007): Bioproduction of therapeutic proteins in the 21st century and the role of plants and plant cells as production platforms. *Annals of the New York Academy of Sciences*, **1102**: 121–134.
- CABANES-MACHETEAU M., FITCHETTE-LAINE A.C., LOUTELIER-BOURHIS C., LANGE C., VINE N., MA J., LEROUGE P., FAYE L. (1999): N-Glycosylation of a mouse IgG expressed in transgenic tobacco plants. *Glycobiology*, **9**: 365–372.
- CARTER J.E., LANGRIDGE W.H. (2002): Plant-based vaccines for protection against infectious and autoimmune diseases. *Critical Reviews in Plant Sciences*, **21**: 93–109.
- CAVENER D.R., RAY S.C. (1991): Eukaryotic start and stop translation sites. *Nucleic Acids Research*, **19**: 3185–3192.
- CHEN M., LIU X., WANG Z., SONG J., QI Q., WANG P.G. (2005): Modification of plant N-glycans processing: the future of producing therapeutic protein by transgenic plants. *Medicinal Research Reviews*, **25**: 343–360.
- CHRISTENSEN A.H., QUAIL P.H. (1996): Ubiquitin promoter-based vectors for high-level expression of selectable and/or screenable marker genes in monocotyledonous plants. *Transgenic Research*, **5**: 213–218.
- CONRAD U., FIEDLER U. (1998): Compartment-specific accumulation of recombinant immunoglobulins in plant cells: An essential tool for antibody production and immunomodulation of physiological functions and pathogen activity. *Plant Molecular Biology*, **38**: 101–109.
- CRAMER C.L., BOOTHE J.G., OISHI K.K. (1999): Transgenic plants for therapeutic proteins: linking upstream and downstream strategies. *Current Topics in Microbiology and Immunology*, **240**: 95–118.
- DANIELL H. (2006): Production of biopharmaceuticals and vaccines in plants via the chloroplast genome. *Biotechnology Journal*, **1**: 1071–1079.
- DANIELL H., DHINGRA A. (2002): Multigene engineering: dawn of an exciting new era in biotechnology. *Current Opinion in Biotechnology*, **13**: 136–141.
- DANIELL H., KUMAR S., DUFOURMANTEL N. (2005): Breakthrough in chloroplast genetic engineering of agronomically important crops. *Trends in Biotechnology*, **23**: 238–245.
- DATLA R.S.S., BEKKAOUI F., HAMMERLINDL J.K., PILATE G., DUNSTAN D.I., CROSBY W.L. (1993): Improved high-level constitutive foreign gene expression in plants using an AMV RNA4 untranslated leader sequence. *Plant Science*, **94**: 139–149.
- DE COSA B., MOAR W., LEE S.B., MILLER M., DANIELL H. (2001): Over-expression of the Bt cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. *Nature Biotechnology*, **19**: 71–74.
- DRAKE P.M., BARBI T., SEXTON A., MCGOWAN E., STADLMANN J., NAVARRE C., MA J.K.C. (2009): Development of rhizosecretion as a production system for recombinant proteins from hydroponic cultivated tobacco. *The FASEB Journal*, **23**: 3581–3589.
- European Parliament (2003): Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on Genetically Modified Food and Feed. *Official Journal of the European Union*, **L268**: 1–23.
- EVANGELISTA R.L., KUSNADI A.R., HOWARD J.A., NIKOLOV Z.L. (1988): Process and economic evaluation of the extraction and purification of recombinant glucuronidase from transgenic corn. *Biotechnology Progress*, **14**: 607–614.
- FINNEGAN J., MCELROY D. (1994): Transgene inactivation: plants fight back. *Bio/Technology*, **12**: 883–888.
- FISCHER R., EMANS N. (2000): Molecular farming of pharmaceutical proteins. *Transgenic Research*, **9**: 279–299.
- FISCHER R., STOGER E., SCHILLBERG S., CHRISTOU P., TWYMAN R.M. (2004) Plant-based production of biopharmaceuticals. *Current Opinion in Plant Biology*, **7**: 152–158.
- FRANKEN E., TEUSCHEL U., HAIN R. (1997): Recombinant proteins from transgenic plants. *Current Opinion in Biotechnology*, **8**: 411–416.
- FU H., MACHADO P.A., HAHM T.S., KRATOCHVIL R.J., WEI C.I., LO Y.M. (2010): Recovery of nicotine-free proteins from tobacco leaves using phosphate buffer system under controlled conditions. *Bioresource Technology*, **101**: 2034–2042.
- GALLIE D. (1998): Controlling gene expression in transgenics. *Current Opinion in Plant Biology*, **1**: 166–172.
- GEORGIU G., BOWDEN G.A. (1991): Inclusion body formation and the recovery of aggregated recombinant proteins. In: HO C., PROKOP A., BAJPAJ R. (eds): *Recombinant DNA Technology and Applications*. McGraw-Hill, New York, 333–356.
- GIDDINGS G., ALLISON G., BROOKS D., CARTER C. (2000): Transgenic plants as factories for biopharmaceuticals. *Nature Biotechnology*, **18**: 1151–1155.
- GODERIS I.J.W.M., DE BOLLE M.F.C., FRANCOIS I.E.J.A., WOUTERS P.F.J., BROEKAERT W.E., CAMMUE B.P.A. (2002): A set of modular plant transformation vectors allowing flexible insertion of up to six expression units. *Plant Molecular Biology*, **50**: 17–27.
- HARASHIMA S. (1994): Heterologous protein production by yeast host-vector systems. *Bioprocess Technology*, **19**: 137–158.
- HELENIUS A., AEBI M. (2001): Intracellular functions of N-linked glycans. *Science*, **291**: 2364–2369.
- HELLEN C.U.T., SARNOV P. (2001): Internal ribosome entry sites in eukaryotic mRNA molecules. *Genes and Development*, **15**: 1593–1612.

- HERBERS K., SONNEWALD U. (1999): Production of new/modified proteins in transgenic plants. *Current Opinion in Biotechnology*, **10**: 163–168.
- HOOD E.E. (2004): Plants as enzyme factories. In: CHRISTOU P., KLEE H. (eds): *Handbook of Plant Biotechnology*, Wiley-VCH, Chichester, 791–800.
- HOUEBINE L.M., ATTAL J. (1999): Internal ribosome entry sites (IRESs): reality and use. *Transgenic Research*, **8**: 157–177.
- HUNT A.G. (1994): Messenger RNA 3' end formation in plants. *Annual Review of Plant Physiology and Plant Molecular Biology*, **45**: 47–60.
- INGELBRECHT I.L.W., HERMAN L.M.F., DEKEYSER R.A., VAN MONTAGU M.C., DEPICKER A.G. (1989): Different 3' end regions strongly influence the level of gene expression in plant cells. *Plant Cell*, **1**: 671–680.
- JOHANSEN L.K., CARRINGTON J.C. (2001): Silencing on the spot. Induction and suppression of RNA silencing in the *Agrobacterium*-mediated transient expression system. *Plant Physiology*, **126**: 930–938.
- KAPILA J., RYCKE R.D., MONTAGU M.V., ANGENON G. (1996): An *Agrobacterium* mediated transient gene expression system for intact leaves. *Plant Science*, **122**: 101–108.
- KAUFMAN R.J., DAVIES M.V., WASLEY L.C., MICHNICK D. (1991): Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus. *Nucleic Acids Research*, **19**: 4485–4490.
- KHOUDI H., LABERGE S., FERULLO J.M., BAZIN R., DARVEAU A., CASTONGUAY Y., ALLARD G., LEMIEUX R., VÉZINA L.P. (1999): Production of a diagnostic monoclonal antibody in perennial alfalfa plants. *Biotechnology and Bioengineering*, **64**: 135–143.
- KLEINER S.M. (1995): The true nature of herbs. *Physician and Sports Medicine*, **23**: 13–14.
- KREBBERS E., BOSCH D., VANDEKERCKHOVE J. (1992): Prospects and progress in the production of foreign proteins and peptides in transgenic plants. In: SHEWRY P.R., GUTTERIDGES S. (eds): *Plant Protein Engineering*. Cambridge University Press, London, 315–325.
- KUSNADI A.R., HOOD E.E., WITCHER D.R., HOWARD J.A., NIKOLOV Z.L. (1998): Production and purification of two recombinant proteins from transgenic corn. *Biotechnology Progress*, **14**: 149–155.
- LI L., ZHOU Y., CHENG X., SUN J., MARITA J.M., RALPH J., CHIANG V.L. (2003): Combinatorial modification of multiple lignin traits in trees through multigene cotransformation. *Proceedings of the National Academy of Sciences of the United States of America*, **100**: 4939–4944.
- LOOS A., STEINKELLNER H. (2012): IgG-Fc glycoengineering in non-mammalian expression hosts. *Archives of Biochemistry and Biophysics*, **526**: 167–173.
- LUBON H., PALEYANDA R.K., VELANDER W.H., DROHAN W.N. (1996): Blood proteins from transgenic animal bioreactors. *Transfusion Medicine Reviews*, **10**: 131–143.
- LUTCKE H.A., CHOW K.C., MICKEL F.S., MOSS K.A., KERN H.F., SCHEELE G.A. (1987): Selection of AUG initiation codons differs in plants and animals. *EMBO Journal*, **6**: 43–48.
- MA J.K.C., LEHNER T., STABILA P., FUX C.I., HIATT A. (1994): Assembly of monoclonal antibodies with IgG1 and IgA heavy chain domains in transgenic tobacco plants. *European Journal of Immunology*, **24**: 131–138.
- MA J.K.C., HIATT A., HEIN M., VINE N.D., WANG F., STABILA P., VAN DOLLEWEERD C., MOSTOV K., LEHNER T. (1995): Generation and assembly of secretory antibodies in plants. *Science*, **268**: 716–719.
- MA J.K.C., DRAKE P.M.W., CHRISTOU P. (2003): The production of recombinant pharmaceutical proteins in plants. *Nature Reviews Genetics*, **4**: 794–805.
- MA J.K.C., DRAKE P.M.W., CHARGELEGUE D., OBREGON P., PRADA A. (2005): Antibody processing and engineering in plants, and new strategies for vaccine production. *Vaccine*, **23**: 1814–1818.
- MAAS C., LAUFS J., GRANT S., KORFHAGE C., WERR W. (1991): The combination of a novel stimulatory element in the first exon of the maize *Shrunken-1* gene with the following intron 1 enhances reporter gene expression up to 1000-fold. *Plant Molecular Biology*, **16**: 199–207.
- MASON H.S., WARZECHA H., MOR T., ARNTZEN C.J. (2002): Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. *Trends in Molecular Medicine*, **8**: 324–329.
- MATTHEWS B.F., HUGHES C.A. (1993): Nutritional improvement of the aspartate family of amino acids in edible crop plants. *Amino Acids*, **4**: 21–34.
- MATZKE A.J.M., MATZKE M.A. (1998): Position effects and epigenetic silencing of plant transgenes. *Current Opinion in Plant Biology*, **1**: 142–148.
- MENASSA R., NGUYEN V., JEVIKAR A., BRANDLE J. (2001): A self-contained system for the field production of plant recombinant interleukin-10. *Molecular Breeding*, **8**: 177–185.
- MEWETT O., JOHNSON H.S., HOLTZAPFFEL R. (2007): *Plant Molecular Farming in Australia and Overseas*. Bureau of Rural Sciences, Canberra, 1–63.
- MEYER P., SAEDLER H. (1996): Homology-dependent gene silencing in plants. *Annual Review in Plant Physiology and Plant Molecular Biology*, **47**: 23–48.
- MORAVEC T., SCHMIDT M.A., HERMAN E.M., WOODFORD-THOMAS T. (2007): Production of *Escherichia coli* heat labile toxin (LT) B subunit in soybean seed and analysis of its immunogenicity as an oral vaccine. *Vaccine*, **25**: 1647–1657.

- NAGELS B., WETERINGS K., CALLEWAERT N., VAN DAMME E.J.M. (2012): Production of plant made pharmaceuticals: from plant host to functional protein. *Critical Reviews in Plant Sciences*, **31**: 148–80.
- PELLETIER J., SONENBERG N. (1988): Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. *Nature*, **334**: 320–325.
- PERRIN Y., VAQUERO C., GERRARD I., SACK M., DROSSARD J., STÖGER E., CHRISTOU P., FISCHER R. (2000): Transgenic pea seeds as bioreactors for the production of a single-chain Fv fragment (scFV) antibody used in cancer diagnosis and therapy. *Molecular Breeding*, **6**: 345–352.
- QIAN B., SHEN H., LIANG W., GUO X., ZHANG C., WANG Y., LI G., WU A., CAO K., ZHANG D. (2008): Immunogenicity of recombinant hepatitis B virus surface antigen fused with preS1 epitopes expressed in rice seeds. *Transgenic Research*, **17**: 621–631.
- RADEMACHER T., SACK M., ARCALIS E., STADLMANN J., BALZER S., ALTMANN F., QUENDLER H., STIEGLER G., KUNERT R., FISCHER R. (2008): Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. *Plant Biotechnology Journal*, **6**: 189–201.
- RAMESSAR K., CAPELL T., TWYMAN R.M., QUEMADA H., CHRISTOU P. (2008): Trace and traceability – a call for regulatory harmony. *Nature Biotechnology*, **26**: 975–978.
- RIGANO M.M., WALMSLEY A.M. (2005): Expression systems and developments in plant-made vaccines. *Immunology and Cell Biology*, **83**: 271–277.
- RUF S., HERMANN M., BERGER I.J., CARRER H., BOCK R. (2001): Stable genetic transformation of tomato plastids and expression of a foreign protein in fruit. *Nature Biotechnology*, **19**: 870–875.
- RUHLMAN T., AHANGARI R., DEVINE A., SAMSAM M., DANIELL H. (2007): Expression of cholera toxin B-proinsulin fusion protein in lettuce and tobacco chloroplasts-oral administration protects against development of insulinitis in non-obese diabetic mice. *Plant Biotechnology Journal*, **5**: 495–510.
- SAINSBURY F., THUENEMANN E.C., LOMONOSOFF G.P. (2009): pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. *Plant Biotechnology Journal*, **7**: 682–693.
- SANDHU J.S., KRASNANSKI S.F., DOMIER L.L., KORBAN S.S., OSADJAN M.D., BUETOW D.E. (2000): Oral immunization of mice with transgenic tomato fruit expressing respiratory syncytial virus-F protein induces a systemic immune response. *Transgenic Research*, **9**: 127–35.
- SASAKI Y., SONE T., YAHATA K., KISHINE H., HOTTA J., CHESNUT J.D., HONDA T., IMAMOTO F. (2008): Multi-gene gateway clone design for expression of multiple heterologous genes in living cells: Eukaryotic clones containing two and three ORF multi-gene cassettes expressed from a single promoter. *Journal of Biotechnology*, **136**: 103–112.
- SCHILLBERG S., TWYMAN R.M., FISCHER R. (2005): Opportunities for recombinant antigen and antibody expression in transgenic plants-technology assessment. *Vaccine*, **23**: 1764–1769.
- SEXTON A., HARMAN S., SHATTOCK R.J., MA J.K.C. (2009): Design, expression, and characterization of a multivalent, combination HIV microbicide. *The FASEB Journal*, **23**: 3590–3600.
- SHARMA A.K., SHARMA M.K. (2009): Plants as bioreactors: recent developments and emerging opportunities. *Biotechnology Advances*, **27**: 811–832.
- SINGH B.K., MATTHEWS B.F. (1994): Molecular regulation of amino acid biosynthesis in plants. *Amino Acids*, **7**: 165–174.
- SLATER S., MITSKY T.A., HOUMIEL K.L., HAO M., REISER S.E., TAYLOR N.B., TRAN M., VALENTIN H.E., RODRIGUEZ D.J., STONE D.A. (1999): Metabolic engineering of Arabidopsis and Brassica for poly (3-hydroxybutyrate-co-3-hydroxyvalerate) copolymer production. *Nature Biotechnology*, **17**: 1011–1016.
- SPARROW P.A.C., TWYMAN R.M. (2009): Biosafety, risk assessment and regulation of plant-made pharmaceuticals. *Methods in Molecular Biology*, **483**: 341–353.
- STOGER E., VAQUERO C., TORRES E., SACK M., NICHOLSON L., DROSSARD J., WILLIAMS S., KEEN D., PERRIN Y., CHRISTOU P., FISCHER R. (2000): Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. *Plant Molecular Biology*, **42**: 583–590.
- SULLIVAN M.L., GREEN P.J. (1993): Post-transcriptional regulation of nuclear-encoded genes in higher plants: the roles of mRNA stability and translation. *Plant Molecular Biology*, **23**: 1091–1104.
- TAYLOR C.B., GREEN P.J. (1995): Identification and characterization of genes with unstable transcripts (GUTs) in tobacco. *Plant Molecular Biology*, **28**: 27–38.
- TREVELYAN J. (1993): Herbal medicine. *Nursing Times*, **89**: 36–38.
- TRIVEDI P.K., NATH P. (2004): MaExp1, an ethylene-induced expansin from ripening banana fruit. *Plant Science*, **167**: 1351–1358.
- TSUBOI T., TAKEO S., IRIKO H., JIN L., TSUCHIMUCHI M., MATSUDA S., HAN E.T., OTSUKI H., KANEKO O., SATTABONGKOT J. (2008): Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. *Infection and Immunity*, **76**: 1702–1708.
- TWYMAN R.M., STOGER E., SCHILLBERG S., CHRISTOU P., FISCHER R. (2003): Molecular farming in plants: host systems and expression technology. *Trends in Biotechnology*, **21**: 570–578.

- VAN DEN ELZEN P.J.M., JONGEDIJK E., MELCHERS L.S., CORNELISSEN B.J.C. (1993): Virus and fungal resistance: From laboratory to field. *Philosophical Transactions: Biological Sciences*, **342**: 271–278.
- VERMA D., DANIELL H. (2007): Chloroplast vector systems for biotechnology applications. *Plant Physiology*, **145**: 1129–1143.
- VERWOERD T.C., VAN PARIDON P.A., VAN OOYEN A.J.J., VAN LENT J.W.M., HOEKEMA A., PEN J. (1995): Stable accumulation of *Aspergillus niger* phytase in transgenic tobacco leaves. *Plant Physiology*, **109**: 1199–1205.
- WHITELAM G.C. (2000): Vaccine production in plants. In: ANDREW P.W., OYSTON P., SMITH G.L. STEWART-TULL D.E. (eds): *Fighting Infection in the 21st Century*. Blackwell Science Ltd., Oxford, 133–142.
- WHITELAM G.C., COCKBURN B., GANDECHA A.R., OWEN M.R.L. (1993): Heterologous protein production in transgenic plants. *Biotechnology and Genetic Engineering Reviews*, **11**: 1–29.
- WINSLOW L.C., KROLL D.J. (1998): Herbs as medicines. *Archives of Internal Medicine*, **158**: 2192–2199.
- YUSIBOV V., HOOPER D.C., SPITSIN S.V., FLEYSH N., KEAN R.B., MIKHEEVA T., DEKA D., KARASEV A., COX S., RANDALL J. (2002): Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. *Vaccine*, **20**: 3155–3164.
- ZHANG S., FAUQUET M. (1998): Expression and inheritance of multiple transgenes in rice plants. *Nature Biotechnology*, **16**: 1060–1064.
- ZHOU Y., ARAN J., GOTTESMAN M.M., PASTAN I. (1998): Co-expression of human adenosine deaminase and multidrug resistance using a bicistronic retroviral vector. *Human Gene Therapy*, **9**: 287–293.
- ZIEGLER M., THOMAS S., DANNA K. (2000): Accumulation of a thermostable endo-1,4- β -D-glucanase in the apoplast of *Arabidopsis thaliana* leaves. *Molecular Breeding*, **6**: 37–46.

Received for publication September 16, 2013

Accepted after corrections December 4, 2013

Corresponding author:

Dr. KAFEEL AHMAD, Centre of Biotechnology and Microbiology, University of Peshawar, Peshawar Khyber Pakhtunkhwa, Pakistan; e-mail: kafeelpbg@gmail.com
